GLYCOPYRROLATE

Search structure


Trade Names:	CUVPOSA GLYCOPYRROLATE GLYRX-PF LONHALA MAGNAIR KIT ROBINUL ROBINUL FORTE SEEBRI
Synonyms:	AD-237 AHR-504 CHF-5259 CHF5259 Cuvposa Glycopyrrolate Glycopyrrolate, erythro- Glycopyrrone bromide Glycopyrronium (as bromide) Glycopyrronium bromide Glyrx-pf Lonhala magnair kit Nodapton NSC-250836 NSC-251251 NSC-251252 NVA-237 NVA237 ORG-NC-45 PT-001 PT001 Robanul Robinul Robinul forte Robinul fte Seebri Sialanar Tarodyl Tarodyn
Status:	Approved (1961)
Entry Type:	Small molecule
Molecule Category:	Parent
UNII:	V92SO9WP2I

Structure


InChI Key	VPNYRYCIDCJBOM-UHFFFAOYSA-M
Smile	C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]
InChI	InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C19H28BrNO3
Molecular Weight	398.34
AlogP	2.46
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	46.53
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	23.0

Pharmacology

Action	Mechanism of Action	Reference
ANTAGONIST	Muscarinic acetylcholine receptor M1 antagonist	ISBN PubMed DailyMed

	Primary Target
M₁ receptor
M₂ receptor
M₃ receptor
M₄ receptor
M₅ receptor

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Acetylcholine receptor	-	0	-	1	-

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Asthma	3	D001249	ClinicalTrials
Burns	3	D002056	ClinicalTrials
Pulmonary Disease, Chronic Obstructive	3	D029424	ClinicalTrials
Hyperhidrosis	2	D006945	ClinicalTrials
Kidney Diseases	1	D007674	ClinicalTrials
Sialorrhea	1	D012798	ClinicalTrials
Depressive Disorder	1	D003866	ClinicalTrials

Related Entries

MCS

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend :

Indication

Mechanism of Action

Primary Target

Target Level

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Mixture

Mixture

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Gastrointestinal disorders Dry mouth	40.0
Gastrointestinal disorders Vomiting	40.0
Gastrointestinal disorders Constipation	35.0
General disorders and administration site conditions Flushing	30.0
Respiratory, thoracic and mediastinal disorders Nasal congestion	30.0
Gastrointestinal disorders Constipation
General disorders and administration site conditions Flushing
Nervous system disorders Headache	15.0
Infections and infestations Sinusitis	15.0
Infections and infestations Upper respiratory tract infection	15.0
Renal and urinary disorders Urinary retention	15.0
Gastrointestinal disorders Dry mouth
Respiratory, thoracic and mediastinal disorders Nasal congestion
Gastrointestinal disorders Vomiting
Nervous system disorders Headache
Infections and infestations Sinusitis
Gastrointestinal disorders Dry mouth	2.4

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Respiratory, thoracic and mediastinal disorders	25.78
General disorders and administration site conditions	12.08
Cardiac disorders	9.36
Nervous system disorders	6.87
Investigations	5.9
Injury, poisoning and procedural complications	5.49
Gastrointestinal disorders	5.06
Infections and infestations	4.7
Psychiatric disorders	4.02
Immune system disorders	3.76
Musculoskeletal and connective tissue disorders	3.51
Vascular disorders	3.42
Skin and subcutaneous tissue disorders	2.83

Cross References

Resources	Reference
ChEBI	90972
ChEMBL	CHEMBL1201027
DrugBank	DB00986
EPA CompTox	DTXSID6023109
FDA SRS	V92SO9WP2I
Guide to Pharmacology	7459
PubChem	67204829
SureChEMBL	SCHEMBL41436
ZINC	ZINC00968301

CONTENTS